Skip to content


Volume 3 Supplement 2

21st European Workshop for Rheumatology Research

  • Meeting abstract
  • Open Access

New antirheumatic effects of biphosphonate treatment

  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Arthritis Research & Therapy20013 (Suppl 2) :P100

  • Received: 15 January 2001
  • Published:


  • Rheumatoid Arthritis
  • Bone Mineral Density
  • Systemic Lupus Erythematosus
  • Erythrocyte Sedimentation Rate
  • Rheumatic Disease

Recently, secondary osteoporosis therapy has been as new strategy for combination treatment rheumatic disease. We have stadied the efficacy of pamidronate treatment in the contexst of combination therapy rheumatic disease.

The complex chek up of 27 patients with rheumatic disease: (rheumatoid arthritis (RA) - 15, systemic lupus erythematosus (SLE) - 3, ankylosing spondilitis (AS) - 2, Reiter syndrome (RS) - 2, sistemic sclerosis (SS) - 1), average age 46,2 year.

In all of them the decrease of bone mineral density were revealed. Patients had standart non-change cytotoxic therapy, were treated with <<Aredia>> (pamidronate, Novartis pharma, 30 mg i.v. infusion). The control clinical and laboratory examination were carry out after 3 and 6 month. In 24 (88,9%) patients significant improvement was observed: decrease the tender-joint count and swollen-joint count of 25 percent; erythrocyte sedimentation rate decreased by 11,5 mm per hour; serum level of antiphospholipide antibodies decreased (P < 0,05), Ig G serum levels and of cyrculating erithroid precursors decreased (P < 0,05); CD 3+, CD 4+, CD 8+, CD 20+ levels were normalysed. The regulary pamidronate infusion may benefit from optimisation of the antirheumatic therapy for patients with secondary osteoporosis.

Authors’ Affiliations

Institute of Clinical Immunology SB RAMS, Novosibirsk, Russia